Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Modified oncolytic virus, composition and use thereof

A technology of oncolytic virus and viral genome, applied in the field of modified oncolytic virus, can solve the problem of insufficient treatment of primary or metastatic tumors

Pending Publication Date: 2021-07-23
GENESAIL BIOTECH SHANGHAI CO LTD
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, oncolytic viruses are not sufficient by themselves to treat primary or metastatic tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modified oncolytic virus, composition and use thereof
  • Modified oncolytic virus, composition and use thereof
  • Modified oncolytic virus, composition and use thereof

Examples

Experimental program
Comparison scheme
Effect test

example

[0210] The following examples are set forth to aid in the understanding of the present disclosure and are not to be construed in any way as limiting the scope of the invention as defined in the claims that follow.

example 1

[0211] Example 1: Virus Construction

[0212] The starting WR strain of vaccinia virus was obtained from the ATCC (www.atcc.org: VR-1354). Since multiple genes are involved, WR-GS-600 was built with a step-by-step engineering approach. Briefly, in the first step, the WR DNA was recombined with the modified pSEM-1 vector (Rintoul et al., 2011) to insert the marker / selection gene into the TK locus. This allows for easy differentiation from the wild type parent for further engineering. Afterwards, the amino acid sequence and the nucleic acid sequence encoding anti-human PD-1, which have flanking sequences of J1R and J3R and encode anti-human PD-1, are shown in Figure 15 and 16 Middle) and anti-human 4-1BB (the amino acid sequence of anti-human 4-1BB and the nucleic acid sequence encoding anti-human 4-1BB are shown in Figure 17 and 18 Middle) recombinant plasmids were transfected into WR-infected U2OS cells to completely delete TK and insert antibody sequences. figure 1 st...

example 2

[0220] Example 2: Characterization of WR-GS-600, WR-GS-610 and WR-GS-620

[0221] During the engineering process of these new viruses, their genome integrity and protein expression were closely monitored.

[0222] PCR, sequencing, and restriction digests

[0223] Genomic DNA of the virus was isolated from a sucrose pad purified by treatment of the virus preparation with the totipotent nuclease endonuclease, by sucrose precipitation, followed by proteinase K and detergent treatment, followed by phenol / chloroform / isoamyl alcohol extraction and ethanol precipitation. Extract and recover DNA.

[0224] To ensure that the viral genome has the expected sequence carrying the designed antibody sequence, a series of primers have been designed, including primers within the recombination region and primers outside the engineered segment. Virus (WR-GS-600, WR-GS-610 and WR-GS-620) identities were confirmed by qPCR (TaqMan). Primers used in PCR are shown in Table 2. The locations of t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided is a modified oncolytic virus having a first heterologous polynucleotide encoding an immune checkpoint inhibitor and a second heterologous polynucleotide encoding an immune activator. Also provided is a pharmaceutical composition comprising the modified oncolytic virus and a method of treating a cancer comprising administering to a subject the modified oncolytic virus or the pharmaceutical composition.

Description

technical field [0001] The present disclosure generally relates to modified oncolytic viruses, compositions comprising the modified oncolytic viruses, and uses thereof in the treatment of tumors. Background technique [0002] Tumors are diagnosed in more than 14 million people worldwide each year. Despite numerous advances in medical research, tumors account for approximately 16% of all deaths. [0003] Malignant tumors are often resistant to conventional therapies and represent a major therapeutic challenge. For example, micrometastases can arise very early in the development of a primary tumor. Thus, at the time of diagnosis, many tumor patients already have microscopic metastases. Tumor-reactive T cells seek out and destroy these micrometastases without harming surrounding healthy tissue. However, naturally occurring T cell responses against malignancy are often insufficient to cause regression of primary or metastatic tumors. [0004] Oncolytic viruses have shown po...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/768C12N15/86C12N15/13A61P35/00C12N7/01
CPCC12N2710/24143C12N2710/24132A61K35/768C07K16/2818C07K16/2878A61K2039/507A61P35/00C07K2317/73C12N7/00
Inventor 岑仡
Owner GENESAIL BIOTECH SHANGHAI CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com